NCT06907602View on ClinicalTrials.gov

Optimizing Neoadjuvant Treatment Regimens for Locally Advanced Esophageal Squamous Cell Carcinoma

PHASE2/PHASE3RecruitingINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

January 12, 2024

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2028

Conditions
Locally Advanced Esophageal Squamous Cell Carcinoma
Interventions
DRUG

Chemotherapy

carboplatin plus nab-paclitaxel

DRUG

Immunotherapy (Pembrolizumab)

Pembrolizumab

RADIATION

radiotherapy

40-45Gy/20fx，5 times a week

Trial Locations (1)

100730

RECRUITING

Peking Union Medical College Hospital, Beijing

All Listed Sponsors
collaborator

Military 301 Hospital

UNKNOWN

collaborator

Peking University Cancer Hospital & Institute

OTHER

collaborator

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

OTHER

lead

Peking Union Medical College Hospital

OTHER